Market Tracker

10/20 5:16pm ET

Exelixis Inc (NASDAQ:EXEL)

27.17
Delayed Data
As of 4:00pm ET
 -0.29 / -1.06%
Today’s Change
10.04
Today|||52-Week Range
32.50
+82.23%
Year-to-Date
Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Dr...
Oct 18 / Zacks.com - Paid Partner Content
Wall Street High on Monday
Oct 16 / GuruFocus News - Paid Partner Content
Company News For Oct 17, 2017
Oct 17 / Zacks.com - Paid Partner Content
Exelixis Pops as FDA Gives Kidney Cancer Drug Priority Review -- Biotech Movers
Oct 16 / TheStreet.com - Paid Partner Content
FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx
Oct 17 / Zacks.com - Paid Partner Content
Exelisis Pops as FDA Gives Kidney Cancer Drug Priority Review -- Biotech Movers
Oct 16 / TheStreet.com - Paid Partner Content
Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session
Oct 17 / Zacks.com - Paid Partner Content
Exelisis Soars After FDA Grants Priority Review for Kidney Cancer Drug
Oct 16 / TheStreet.com - Paid Partner Content
Wall Street High on Monday
Oct 16 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close27.46
Today’s open27.31
Day’s range27.06 - 27.83
Volume2,740,852
Average volume (3 months)4,301,746
Market cap$8.1B
Dividend yield--
Data as of 4:00pm ET, 10/20/2017

Growth & Valuation

Earnings growth (last year)+65.43%
Earnings growth (this year)+196.43%
Earnings growth (next 5 years)+46.00%
Revenue growth (last year)+415.05%
P/E ratio113.2
Price/Sales19.51
Price/Book89.14

Competitors

 Today’s
change
Today’s
% change
ICLRICON PLC-0.73-0.64%
CRLCharles River Labora...-0.18-0.16%
PRAHPRA Health Sciences ...+0.28+0.34%
----
Data as of 4:02pm ET, 10/20/2017

Financials

Next reporting dateNovember 8, 2017
EPS forecast (this quarter)$0.08
Annual revenue (last year)$191.5M
Annual profit (last year)-$70.2M
Net profit margin-36.68%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Michael M. Morrissey
Executive VP, Chief Financial &
Accounting Officer
Christopher J. Senner
Corporate headquarters
South San Francisco, California

Forecasts